Risk of gastroparesis with common weight loss drug

The use of the glucagon-like peptide-1 receptor agonist semaglutide could elevate the risk of gastroparesis among patients with obesity.

In a retrospective study published in BMJ Open Gastroenterology, investigators used the Merative MarketScan Research Databases to examine the outcomes of patients who received one of three treatment modalities: Semaglutide, bupropion-naltrexone or sleeve gastrectomy.

The investigators identified a higher incidence of gastroparesis among the patients who received semaglutide compared with those who received bupropion-naltrexone or sleeve gastrectomy. Factors predictive of gastroparesis included metabolic dysfunction-associated fatty liver disease, gastroesophageal reflux disease and a body mass index between 30 and 34.

The investigators hope their insights can better inform treatment decision-making among patients with obesity and their physicians.

Read more: BMJ Open Gastroenterology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.